Three terms the labels use
What the current labels report
The figures below are the adult weight-reduction trial incidences reported in the current labels. [1] [2]
| Label and trial context | Cholelithiasis | Cholecystitis | Cholecystectomy |
|---|---|---|---|
| Wegovy adult weight-reduction injection trials | 1.6% Wegovy vs 0.7% placebo | 0.6% vs 0.2% | Not listed in this label passage |
| Zepbound pooled adult weight-reduction Studies 1 and 2 | 1.1% Zepbound vs 1.0% placebo | 0.7% vs 0.2% | 0.2% vs 0% |
Weight loss and the medicine signal: what can be separated
The Wegovy label says substantial or rapid weight loss can increase the risk of cholelithiasis. It also says acute gallbladder disease occurred more often with Wegovy than placebo even after accounting for degree of weight loss. [1]
The Zepbound label says acute gallbladder events in its pooled weight-reduction trials were associated with weight reduction. [2]
What the randomized-trial meta-analysis adds
A 2022 systematic review and meta-analysis included 76 randomized clinical trials and 103,371 adults. Randomization to a GLP-1 receptor agonist was associated with higher risk of gallbladder or biliary disease (relative risk 1.37; 95% confidence interval 1.23–1.52), cholelithiasis (RR 1.27), and cholecystitis (RR 1.36). The association was stronger in weight-loss trials (RR 2.29), and in higher-dose and longer-duration subgroup analyses. The authors’ search covered sources through June 30, 2021. [3]
Boundary: these are associations across trials, not a mechanism, proof of what caused an event in one person, or a way to predict an individual outcome. The literature cutoff also matters when reading the result. [3]
What evaluation can include
NIDDK describes gallstone diagnosis as using medical history, physical examination, laboratory tests, and imaging. Blood tests can show signs of infection or inflammation involving the bile ducts, gallbladder, pancreas, or liver; NIDDK describes ultrasound as the best imaging test for finding gallstones. [4]
This is a description of possible clinical evaluation, not a test recommendation. Which tests are relevant and how results are interpreted belong to the clinician. The labels connect diagnostic evaluation to suspected cholelithiasis or cholecystitis rather than defining one universal routine panel or calendar. [1] [2]
Symptoms NIDDK says require care right away
NIDDK says to seek care right away for abdominal pain lasting several hours, nausea and vomiting, fever or chills, jaundice, tea-colored urine, or light-colored stools. Upper-right abdominal pain can last several hours. These symptoms overlap with other conditions and cannot diagnose gallbladder disease. [5]
Build a clean event timeline
A neutral record keeps clinical context together without deciding what it means:
Exact product name plus clinician-directed schedule and change dates.
Preserve exact dates as recorded.
Onset, duration, and location in plain language.
Vomiting, fever, jaundice, and urine or stool changes only if observed.
Keep dated measurements together without assigning cause.
Original lab and imaging reports, clinical contacts, and documented outcomes.
Neutral documentation does not diagnose gallbladder disease or establish cause.
Questions for the prescriber
- How does the current label language apply to my documented history?
- Which symptoms would change the preferred contact plan?
- If gallbladder disease is suspected, what evaluation is planned?
- Which original lab, imaging, and treatment records should I bring?
Preserve the sequence
Keep the clinician-directed plan and event dates together
Jabbit supports smart scheduling, injection logging, and weight tracking in one place. It cannot diagnose gallbladder disease, interpret symptoms or tests, or determine causation.
Track your protocol timeline in JabbitFrequently asked questions
Is there a universal routine gallbladder test for everyone using a GLP-1 medicine?
The Wegovy and Zepbound labels tie gallbladder studies or diagnostic studies to suspected cholelithiasis or cholecystitis. They do not define a universal routine gallbladder blood panel or screening calendar. Test selection and interpretation belong to the clinician. [1] [2]
Do the label trial percentages predict my personal gallbladder risk?
No. The percentages describe specific trial populations. The Wegovy and Zepbound figures also come from different trials, so they are not a head-to-head comparison or an individual prediction. [1] [2]
Does weight loss fully explain the gallbladder signal?
The evidence does not support that simple conclusion. Both labels connect gallbladder events with weight reduction, and the Wegovy label says acute gallbladder disease remained more frequent with Wegovy after accounting for degree of weight loss. A 2022 meta-analysis found an association across randomized GLP-1 receptor agonist trials, but it does not prove a mechanism or predict an individual outcome. [1] [2] [3]
What records can help a clinician review a possible gallbladder event?
A neutral timeline can include the exact product name, clinician-directed schedule and change dates, injection dates, symptom onset and duration, observed vomiting, fever, jaundice, urine or stool changes, weight trend, original lab or imaging reports, and clinical contacts and outcomes. Documentation does not diagnose gallbladder disease or establish cause.
Sources opened and checked
- [1]Current Wegovy prescribing information, DailyMed, section 5.3.
- [2]Current Zepbound prescribing information, DailyMed, section 5.4.
- [3]He et al., JAMA Internal Medicine, 2022; PMID 35344001; DOI 10.1001/jamainternmed.2022.0338.
- [4]NIDDK, Diagnosis of Gallstones.
- [5]NIDDK, Symptoms & Causes of Gallstones.
- [6]MedlinePlus, Gallstones (Cholelithiasis).
- [7]MedlinePlus Medical Encyclopedia, Acute cholecystitis.
- [8]MedlinePlus Medical Encyclopedia, Open gallbladder removal.
Sources checked August 28, 2026.